WallStSmart
OCUL

Ocular Therapeutix Inc

NASDAQ: OCUL · HEALTHCARE · BIOTECHNOLOGY

$9.21
-1.18% today

Updated 2026-04-29

Market cap
$2.00B
P/E ratio
P/S ratio
38.59x
EPS (TTM)
$-1.42
Dividend yield
52W range
$6 – $16
Volume
4.9M

WallStSmart proprietary scores

24
out of 100
Grade: F
Strong Sell
Investment rating
3.3
Growth
D
5.8
Quality
C+
2.5
Profitability
F
5.0
Valuation
C+
4/9
Piotroski F-Score
Moderate
-2.1
Altman Z-Score
Distress
Industry rank
View all highly rated stocks (75+) →201 stocks currently score above 75

Price targets

Analyst target
$26.00
+182.30%
12-Month target
Intrinsic (DCF)
Margin of safety
4 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths
Insufficient data
Risks
- Altman Z -2.07 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-57.09M
- Revenue declining -22.40% QoQ

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$51.49M$58.44M$63.72M$51.82M$51.95M
Net income$-71.04M$-80.74M$-193.51M$-265.94M$-64.65M
EPS$-1.42
Free cash flow$-63.32M$-76.32M$-135.97M$-216.89M$-57.09M
Profit margin-137.95%-138.14%-303.67%-513.17%

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
OCUL$2.00B243.32.55.05.8Avoid
LLY$760.43B7810.010.05.06.5Strong Buy
JNJ$547.28B594.79.03.36.0-43.54%Buy
ABBV$360.63B634.08.04.75.0-29.31%Buy
UNH$322.34B545.35.57.34.8+42.06%Buy
AZN$294.17B646.78.05.35.0+4.07%Buy

Smart narrative

Ocular Therapeutix Inc trades at $9.21. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -2.07, it sits in the distress. TTM revenue stands at $51.95M.

Frequently asked questions

What is Ocular Therapeutix Inc's stock price?
Ocular Therapeutix Inc (OCUL) trades at $9.21.
Is Ocular Therapeutix Inc overvalued?
Smart Value Score 24/100 (Grade F, Strong Sell).
What is the price target of Ocular Therapeutix Inc (OCUL)?
The analyst target price is $26.00, representing +182.3% upside from the current price of $9.21.
What is Ocular Therapeutix Inc's revenue?
TTM revenue is $51.95M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
-2.07 — distress.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio38.59x
ROE-54.80%
Beta0.95
50D MA$8.93
200D MA$11.06
Shares out0.22B
Float0.22B
Short ratio
Avg volume4.9M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years